A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Trombocitopenia farmacógena (medicamentosa)
El primer paso para tratar este tipo de conteo bajo de plaquetas es dejar de usar el fármaco que puede estar causando el problema.
Para las personas que tienen sangrado potencialmente mortal, los tratamientos pueden abarcar:
El sangrado puede ser mortal si ocurre en el cerebro u otros órganos.
Una mujer embarazada que tenga anticuerpos contra las plaquetas puede pasarle dichos anticuerpos al bebé en el útero.
Warkentin TE. Thrombocytopenia due to platelet destruction and hypersplenism. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hoffman Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier; 2008:chap 140.
McMillan R. Hemorrhagic disorders: abnormalities of platelet and vascular function. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 179.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885